Arora Aastha, Singh Saurabh, Bhatt Anant Narayan, Pandey Sanjay, Sandhir Rajat, Dwarakanath Bilikere S
Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India.; Department of Biochemistry, Panjab University, Chandigarh, India.
Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India.
Transl Oncogenomics. 2015 Dec 29;7:11-27. doi: 10.4137/TOG.S29652. eCollection 2015.
Cancer is a complex disease that arises from the alterations in the composition and regulation of several genes leading to the disturbances in signaling pathways, resulting in the dysregulation of cell proliferation and death as well as the ability of transformed cells to invade the host tissue and metastasize. It is increasingly becoming clear that metabolic reprograming plays a critical role in tumorigenesis and metastasis. Therefore, targeting this phenotype is considered as a promising approach for the development of therapeutics and adjuvants. The process of metabolic reprograming is linked to the activation of oncogenes and/or suppression of tumor suppressor genes, which are further regulated by microRNAs (miRNAs) that play important roles in the interplay between oncogenic process and metabolic reprograming. Looking at the advances made in the recent past, it appears that the translation of knowledge from research in the areas of metabolism, miRNA, and therapeutic response will lead to paradigm shift in the management of this disease.
癌症是一种复杂的疾病，它源于多个基因的组成和调控发生改变，导致信号通路紊乱，进而造成细胞增殖和死亡失调，以及转化细胞侵袭宿主组织和发生转移的能力异常。越来越清楚的是，代谢重编程在肿瘤发生和转移中起着关键作用。因此，针对这种表型被认为是开发治疗药物和佐剂的一种有前景的方法。代谢重编程过程与癌基因的激活和/或肿瘤抑制基因的抑制有关，而这些又受到微小RNA（miRNA）的进一步调控，miRNA在致癌过程与代谢重编程的相互作用中发挥重要作用。从最近取得的进展来看，似乎将代谢、miRNA和治疗反应等领域的研究知识转化应用，将导致这种疾病管理模式的转变。
